BI Asset Management Fondsmaeglerselskab A S Raises Stock Holdings in AbbVie Inc. $ABBV

BI Asset Management Fondsmaeglerselskab A S increased its stake in AbbVie Inc. (NYSE:ABBV) by 57.0% during the 1st quarter, Holdings Channel reports. The firm owned 450,556 shares of the company’s stock after purchasing an additional 163,535 shares during the quarter. AbbVie comprises approximately 1.0% of BI Asset Management Fondsmaeglerselskab A S’s portfolio, making the stock its 18th biggest holding. BI Asset Management Fondsmaeglerselskab A S’s holdings in AbbVie were worth $97,815,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of ABBV. Chelsea Counsel Co. bought a new position in shares of AbbVie in the 3rd quarter worth $26,000. Litman Gregory Wealth Management LLC purchased a new stake in shares of AbbVie during the 4th quarter valued at $28,000. Westend Capital Management LLC bought a new stake in shares of AbbVie during the 4th quarter worth $29,000. Imprint Wealth LLC grew its position in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock worth $29,000 after acquiring an additional 45 shares in the last quarter. Finally, Texas Capital Bancshares Inc TX purchased a new position in AbbVie in the third quarter worth $31,000. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Up 0.1%

Shares of NYSE:ABBV opened at $216.63 on Monday. The stock has a market cap of $382.74 billion, a PE ratio of 106.71, a PEG ratio of 0.66 and a beta of 0.32. The company’s fifty day moving average is $212.18 and its 200 day moving average is $218.72. AbbVie Inc. has a 52 week low of $181.73 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period in the prior year, the business posted $2.46 earnings per share. The company’s revenue was up 12.4% on a year-over-year basis. Sell-side analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be issued a dividend of $1.73 per share. The ex-dividend date is Wednesday, July 15th. This represents a $6.92 annualized dividend and a yield of 3.2%. AbbVie’s dividend payout ratio is currently 340.89%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie is reportedly close to buying Apogee Therapeutics for about $10.9 billion, a move that could strengthen its eczema and inflammatory-disease pipeline and support longer-term growth. AbbVie nears $11 billion deal for Apogee Therapeutics, FT reports
• Positive Sentiment: AbbVie’s recent pipeline momentum, including SKINVIVE approval and promising CLL trial results, reinforces confidence in its R&D engine and diversification beyond core immunology drugs. AbbVie (ABBV) Lands New SKINVIVE Approval As CLL Trial Results Impress
• Neutral Sentiment: AbbVie announced a quarterly dividend of $1.73 per share, underscoring its strong cash generation and shareholder-return profile. AbbVie Declares Quarterly Dividend
• Neutral Sentiment: AbbVie is also highlighting its oncology strategy at ASCO 2026, but this is more of a long-term strategic update than an immediate stock catalyst. ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of oncology
• Negative Sentiment: AbbVie’s shares had recently been under pressure as the market moved higher, reflecting some near-term investor caution before the acquisition news. AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
• Negative Sentiment: AbbVie is facing ongoing litigation risk after HHS asked a court to dismiss its suit over drug-discount patients, which could create headline overhang. HHS Asks Court to Toss AbbVie Suit Over Drug Discount Patients

Analysts Set New Price Targets

A number of equities research analysts have weighed in on ABBV shares. William Blair restated an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. BMO Capital Markets reiterated an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Canaccord Genuity Group increased their price objective on AbbVie from $262.00 to $265.00 and gave the company a “buy” rating in a research report on Thursday, April 30th. Royal Bank Of Canada assumed coverage on AbbVie in a report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. Finally, DZ Bank upgraded AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Three analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $253.43.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.